Image courtesy of Abbott Laboratories
Diagnostic companies across the world stepped up this year to bring much-needed testing to the COVID-19 frontlines. But Abbott emerged as a leading test maker in this battle early on.
By mid-April, the company had launched three COVID-19 tests with a fourth test on the way. By October, Abbott had seven COVID-related tests on the market. The company's ID Now rapid point-of-care platform in particular received national attention as the first rapid test to receive an emergency use authorization from FDA for the detection of SARS-CoV-2.
Abbott also made headlines in June after FDA cleared the Freestyle Libre 2 interoperable continuous glucose monitoring (iCGM) system.
Abbott is no stranger to the MD+DI Medtech Company of the Year finalist roster. Our editors named Abbott the 2017 Company of the Year because of the leadership the company showed in the face of numerous obstacles that year.